Drug
brepocitinib
Marketed as LISRAYA.
Generic name
brepocitinib
Brand names
LISRAYA
First FDA approval
2026-08-27
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA220106 | LISRAYA | 2026-08-27 | PRIOVANT THERAP |
Manufacturers
PRIOVANT THERAP
Frequently asked questions
When was brepocitinib FDA approved?
Earliest FDA approval on record: 2026-08-27.
What brand names are sold as brepocitinib?
LISRAYA.
Sources
Appeal a brepocitinib denial
Upload the denial notice. DenialHelp helps verify the reason, organize source-linked evidence, and prepare a treating-clinician-reviewable package. Price and refund terms are shown before payment.
Get started →Contact: hello@denialhelp.com